Laboratory; Research; Biomarker; Clinical Testing

4C - Proteomics in Individualized Medicine
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Tuesday, October 10
1:20 PM - 2:50 PM

This session will focus on mass spectrometry-based proteomic approaches to facilitate individualized medicine. Proteins are the functional effectors of disease processes as well as the direct targets for many new therapeutic agents. Accordingly, cutting-edge proteomic technologies are uncovering unprecedented opportunities to develop new clinical biomarkers and design improved strategies to guide therapy.

Learning Objectives:

Andrew Feldman

Professor of Laboratory Medicine and Pathology
Mayo Clinic

Andrew L. Feldman, M.D., is a Consultant in the Division of Hematopathology at Mayo Clinic, Rochester, Minnesota; Vice Chair for Research in the Department of Laboratory Medicine and Pathology; and Professor of Laboratory Medicine and Pathology in the Mayo Clinic College of Medicine. His clinical interest is in the diagnosis, classification, and personalized therapy of lymphoma. His research program uses integrated, high-throughput molecular profiling to understand the pathogenesis of T-cell lymphomas and to develop new biomarkers to stratify lymphoma patients for risk-adapted and targeted therapies.

Presentation(s):

Send Email for Andrew Feldman

David Murray

Assistant Professor of Laboratory Medicine and Pathology
Mayo Clinic

David L. Murray MD, PhD, is a consultant pathologist and Co-Director of the protein immunology laboratories at Mayo clinic. Dr. Murray oversees clinical for complement disorders, auto-immune diseases and monoclonal gammopathies.

Presentation(s):

Send Email for David Murray

Daniel C. Liebler

President
Protypia, LLC

Daniel C. Liebler, PhD, is President and Founder of Protypia, LLC and Adjunct Professor of Biochemistry at the Vanderbilt University School of Medicine. Dr. Liebler’s research program has focused for 30 years on the application of analytical technology—particularly mass spectrometry—to study the interactions of chemicals with biological systems. His group has made important contributions to the fields of antioxidant chemistry, toxicology mechanisms, proteomics, chemical biology and cancer proteogenomics. Dr. Liebler has authored 295 peer reviewed publications. Dr. Liebler and his colleagues, through the Ayers Institute at Vanderbilt and through the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) network led the development, evaluation and standardization of MS proteomics platforms to application in translational research and clinical diagnostics. The Liebler group and CPTAC collaborators were the first to integrate proteomics and genomics to trace the path from genomic alterations through proteins to cancer phenotypes. Their 2014 study in Nature of colon and rectal tumors was the first proteogenomic analysis of a human cancer.

Prior to forming Protypia, Dr. Liebler was Professor of Biochemistry, Pharmacology and Biomedical Informatics at Vanderbilt (2003-2016). He served as Director of the Jim Ayers Institute for Precancer Detection and Diagnosis at Vanderbilt form 2006-2015. Dr. Liebler served on the faculty of the Department of Pharmacology and Toxicology in the College of Pharmacy at the University of Arizona (1987-2003). Dr. Liebler received a B.S. in Chemistry from Villanova University and a Ph.D. in Pharmacology from Vanderbilt, where he trained in the laboratory of F. Peter Guengerich. He did postdoctoral training in the laboratory of Donald J. Reed at Oregon State University. He was elected Fellow of the American Association for the Advancement of Science in 2008 and was elected Fellow of the American Chemical Society in 2013.

Presentation(s):

Send Email for Daniel Liebler

Joshua J. Coon

Professor of Biomolecular Chemistry and Chemistry
University of Wisconsin-Madison

Joshua Coon, PhD, is a professor of chemistry at the University of Wisconsin–Madison. He grew up in rural Michigan and during these formative years greatly enjoyed fly fishing and woodworking. Putting the latter interest to practical use, he constructed several riverboats (for fishing) while in high school and college. Chemistry interested him, especially Analytical Chemistry, as it offered an avenue to continue “building”. Not boats, but chemical instrumentation. To escape the cold he joined the Chemistry graduate program at the University of Florida and worked with Willard Harrison. Professor Harrison didn’t just guide his research, he taught him how to write, present, and think like a scientist. Upon graduation in 2002, Coon moved to Charlottesville, Virginia to join the laboratory of Professor Don Hunt. At Virginia he met John Syka. Don and John both shared a passion for science that was as infectious as it was inspiring. Together they worked to develop electron transfer dissociation (ETD). ETD worked just as we had hoped and the dissociation technique is now commonly used for proteomics and has been commercially introduced by no fewer than four major instrument vendors. In 2005 Coon moved to Wisconsin to start his own program. And though they have been productive and impactful with ~ 200 published manuscripts, he is most proud to have produced nearly 20 Ph.D. scientists, and their academic family continues to grow.

Presentation(s):

Send Email for Joshua Coon


Assets

4C - Proteomics in Individualized Medicine
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Proteomics in Individualized Medicine
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5